Colorectal cancer

Colorectal cancer | NICE guideline [NG151] | January 2020

This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease).

Recommendations

This guideline includes recommendations on:

See also: Colorectal cancer (Quality Standard 20, updated from Aug 2012)

[NICE Guideline] Prostate cancer: diagnosis and management [NG131]

NICE |  May 2019 | Prostate cancer: diagnosis and management NICE guideline [NG131]

This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

Full details from NICE 

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance [TA554]

NICE | December 2018 | Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years | Technology appraisal guidance [TA554]

 

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years.

 

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

 

See also: NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA555]

NICE | January 2019 |Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA555]

 

Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.

Full details from NICE 

New Quality standard: Oesophago-gastric cancer

This NICE quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.

Quality statements

Statement 1 Adults with oesophago-gastric cancer have access to an oesophago-gastric clinical nurse specialist.

Statement 2 Adults with oesophago-gastric cancer have their treatment reviewed by a multidisciplinary team that includes an oncologist and a specialist radiologist who both have an interest in oesophago-gastric cancer.

Statement 3 Adults with oesophageal or gastro-oesophageal junctional tumours (except T1a tumours) for whom radical treatment is suitable, have 18‑fluorodeoxyglucose positron emission tomography requested and reported within 1 week.

Statement 4 Adults with oesophago-gastric cancer have tailored specialist dietetic support before and after radical treatment.

Full detail: NICE | Oesophago-gastric cancer | Quality standard [QS176]

See also:  NICE interactive flowchart – Oesophageal and gastric cancer